OakChart

CytomX Therapeutics Inc

CTMXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 2:17 PM ET

2.14+0.16 (8.08%)
2026-11-11 20:18 CET
Market cap
431.65 USD m
Revenue, TTM
14.03 USD m
Net income, TTM
-88.42 USD m
Free cash flow, TTM
-51.00 USD m
EPS diluted, TTM
-0.46
P/E
-
Compare

Price

CTMX against its 20, 50 and 200-day averages
2050200miss
2.003.004.0014.4M28.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CTMXclose 2.1420-day 2.2750-day 2.63200-day 3.752.1452w low

73.9% under the 52-week high of 8.21 on 16 Mar 2026. 52-week low 1.90 on 10 Nov 2026. Last 15 sessions, 30.0% high to low

Profile

CTMX
52-week range, 4% of the way up
1.908.21

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies to address unmet need in oncology. The firm focuses on the field of antibody masking technologies through the development of its Probody therapeutic platform. The company was founded by Frederick W. Gluck, Nancy E. Stagliano, and Patrick S. Daugherty in February 2008 and is headquartered in South San Francisco, CA.

IndexRUT
Employees69
IPOOct 08, 2015
Beta2.26
ATR, 14d0.18
Rel volume0.91
Short float25.60%
Insider own18.91%
Inst own94.45%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap466.53M
Enterprise Value122.02M
Income-88.42M
Sales14.03M
Book/sh1.31
Cash/sh1.60
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees69
IPOOct 08, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S33.25
P/B1.64
P/C1.34
P/FCF-
EV/EBITDA-
EV/Sales8.70
Quick Ratio7.82
Current Ratio7.82
Debt/Eq0.02
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.46
EPS next Y-0.50
EPS next Q-0.08
EPS this Y-159.53%
EPS next Y-28.39%
EPS next 5Y-
EPS past 3/5Y53.93% 27.00%
Sales past 3/5Y12.75% -5.36%
EPS Y/Y TTM-210.45%
Sales Y/Y TTM-87.66%
EPS Q/Q-5.92%
Sales Q/Q-71.69%
EarningsNov 05 AMC
EPS/Sales Surpr.-25.17% -83.73%

Ownership

Insider Own18.91%
Insider Trans-0.00%
Inst Own94.45%
Inst Trans2.25%
ROA-32.67%
ROE-43.55%
ROIC-29.58%
Gross Margin91.28%
Oper. Margin-676.46%
Profit Margin-630.38%
SMA20-5.76%
SMA50-18.68%
SMA200-42.87%
Trades-

Technical

Shs Outstand217.95M
Shs Float176.77M
Short Float25.60%
Short Ratio11.09
Short Interest45.25M
52W High8.21 -73.93%
52W Low1.90 12.63%
Volatility10.04% 7.96%
ATR (14)0.18
RSI (14)42.41
Beta2.26
Rel Volume0.91
Avg Volume4.08M
Volume2,786,290

Performance

Perf Week-8.94%
Perf Month-7.96%
Perf Quarter-36.12%
Perf Half Y-43.54%
Perf YTD-49.77%
Perf Year-47.80%
Perf 3Y82.91%
Perf 5Y-69.47%
Perf 10Y-80.91%
Recom1.12
Target Price12.25
Prev Close1.98
Price2.14
Change %8.08%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
May 19, 2026InitiatedWWolfe ResearchOutperform$6+180.4%
Mar 16, 2026UpgradeJJP MorganNeutral → Overweight$12+460.7%
Jan 20, 2026InitiatedGGuggenheimBuy$10+367.3%
Sep 22, 2025InitiatedCCantor FitzgeraldOverweight$6+180.4%
Sep 17, 2025ResumedBBarclaysOverweight$3.50+63.6%
Jul 31, 2025InitiatedOOppenheimerOutperform$7+227.1%
May 15, 2025UpgradeHH.C. WainwrightNeutral → Buy$5+133.6%
Apr 14, 2025ResumedPPiper SandlerOverweight$3.25 → $2.50+16.8%
May 28, 2024UpgradePPiper SandlerNeutral → Overweight$2.25 → $3.50+63.6%
May 09, 2024UpgradeWWedbushNeutral → Outperform$8+273.8%

Peers

Mkt cap
TickerCompanyMkt cap
JANXJanux Therapeutics Inc754.81M
STROSutro Biopharma Inc169.13M
IMNMImmunome Inc2.26B
VIRVir Biotechnology Inc2.25B
XLOXilio Therapeutics Inc55.74M
ZYMEZymeworks BC Inc2.02B
PYXSPyxis Oncology Inc196.49M
MGNXMacrogenics Inc153.49M
BCYCBicycle Therapeutics Plc ADR186.53M
ADCTAdc Therapeutics SA202.99M

Insider trading

5 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ogden ChristopherChief Financial OfficerJun 15 '26Sale3.051,6244,953295,324Jun 17 06:38 PM
Chu Yu-WayeChief Medical OfficerMar 17 '26Sale6.4221,279136,675189,446Mar 19 06:41 PM
McCarthy Sean A.CEOMar 17 '26Sale6.42118,969764,1381,078,922Mar 19 06:35 PM
BELVIN MARCIASVP, Chief Scientific OfficerMar 17 '26Sale6.4231,492202,273300,760Mar 19 06:25 PM
Ogden ChristopherChief Financial OfficerMar 17 '26Sale6.4219,323124,112296,948Mar 19 06:21 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VHTVanguard Health Care ETFAUM: 21.51B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 200
  • CytomX Matches On EPS, But Varseta-M Data Slips To 2027 Shift The Burden To January (Earnings Whispers) -8.94%
  • CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press)
  • CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • CytomX Therapeutics to Present at Upcoming November Investor Conferences (GlobeNewswire)
  • CytomX Stock Near Lows As Investors Seek Proof Varsetta M Is On Pivotal Track (Earnings Whispers)
  • CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
  • CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire) +9.23%
  • CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) (GlobeNewswire)
  • CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... (GuruFocus.com)
  • CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press)
  • CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer (GlobeNewswire)
  • CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
  • CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.090-0.072-0.0901.6910.388
2026Q22026-08-06-0.090-0.077-0.0941.4212.398
2026Q12026-05-07-0.100-0.121-0.10310.264.689
2025Q42026-03-16-0.173-0.093-0.1730.667.339
2025Q32025-11-06-0.090-0.049-0.0865.9611.438
2025Q22025-08-070.000-0.063-0.00118.6618.777
2025Q12025-05-120.2700.1250.27050.9235.525
2024Q42025-03-060.220-0.1950.23638.0913.046
2024Q32024-11-070.070-0.1720.06733.4317.107
2024Q22024-08-08-0.080-0.100-0.07725.1220.007
2024Q12024-05-080.170-0.1020.16741.4619.357
2023Q42024-03-110.020-0.0480.01226.6119.608
2023Q32023-11-070.040-0.1890.03726.3813.349
2023Q22023-08-08-0.020-0.189-0.01624.7213.689
2023Q12023-05-09-0.050-0.111-0.05023.5019.919
2022Q42023-03-27-0.420-0.236-0.1330.9518.079

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.260-1.942-2.25557.4967.28
2020FY-0.710-0.911-0.713100.3699.93
2021FY-1.300-1.262-1.80669.5769.41
2022FY-1.510-1.290-1.51153.1672.04
2023FY-0.010-0.070-0.008101.2194.20
2024FY0.380-0.0430.376138.1115.66
2025FY-0.150-0.028-0.15076.2082.92
2026FY--0.389--20.45
2027FY--0.499--31.21
2028FY--0.473--28.61
2029FY--0.368--54.38
2030FY-0.063--200.46

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-066309.791.7217.90
2026Q4S2026-10-266005.291.7210.00
2026Q4S2026-10-216015.291.7210.00
2026Q4S2026-08-166125.291.7210.00
2026Q4S2026-08-126225.291.7210.00
2026Q4S2026-08-076217.284.0013.65
2026Q4S2026-07-256107.110.0013.65
2026Q4S2026-07-226207.110.0013.65
2026Q4S2026-06-116307.110.0013.65
2026Q4S2026-06-027306.520.0013.65
2026Q4S2026-05-307216.090.0013.65
2026Q4S2026-05-197226.090.0013.65
2026Q4S2026-05-118326.580.0013.65
2026Q4S2026-05-088225.010.0010.00

Estimate history

EPS, annual-1.16-2.031-2.255-0.713-1.806-1.511-0.0080.376-0.148-0.462
Period201720182019202020212022202320242025TTM
EPS, quarterly0.0670.2360.27-0.001-0.086-0.173-0.103-0.094-0.091
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual71.62359.50257.489100.36237.31253.163101.214138.10376.20114.03
Period201720182019202020212022202320242025TTM
Sales, quarterly33.43238.09350.91718.6585.9630.66310.2581.4181.688
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual38.47945.08345.52348.25265.39366.22867.31180.1170.186217.953
Period201720182019202020212022202320242025MRQ
Shares, quarterly78.23380.180.621164.911165.07170.186217.694217.899217.953
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue14.0376.20138.10101.2153.1637.31100.3657.4959.50
Cost of Goods Sold Incl. D&A1.221.381.772.175.865.84---
Gross Profit12.8074.83136.3499.0447.3131.47---
Selling, General and Administrative Excl. Other107.6994.39111.34105.52140.94147.51143.51165.78135.49
Research and Development73.4565.8081.7675.65104.05111.63110.51131.62103.87
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-94.89-19.5625.00-6.48-93.64-116.04-48.60-110.89-77.87
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.002.800.000.007.700.000.00--
Net Income Before Taxes-85.19-17.1332.093.32-99.32-115.87-46.80-102.67-70.30
Income Taxes0.230.240.223.890.000.00-13.91-0.4314.30
Consolidated Net Income-85.42-17.3731.87-0.57-99.32-115.87-32.88-102.24-84.60
Net Income From Continuing Operations-85.42-17.3731.87-0.57-99.32-115.87-32.88-102.24-84.60
Net Income-88.42-20.3731.87-0.57-99.32-115.87-32.88-102.24-84.60
EPS (Recurring)-0.40-0.130.38-0.01-1.43-1.81-0.71-2.26-2.03
EPS (Basic, Before Extraordinaries)-0.46-0.150.38-0.01-1.51-1.81-0.71-2.26-2.03
EPS (Diluted)-0.46-0.150.38-0.01-1.51-1.81-0.71-2.26-2.03
EBITDA-93.66-18.1926.76-4.31-87.78-110.20-43.15-108.29-75.99
Non-Operating Income (Expense)9.705.237.109.812.020.171.818.237.57
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.174.986.066.7613.1213.1710.7913.9413.33
Price To Earnings Ratio--6.07------
Price To Sales Ratio42.497.710.631.131.987.443.016.5510.57
Gross Margin91.2898.1998.7297.8588.9884.35---
Operating Margin-676.46-25.6718.10-6.41-176.13-311.00-48.43-192.90-130.88
Net Margin-630.38-26.7323.08-0.56-186.82-310.54-32.77-177.84-142.19
Shares Outstanding217.95170.1980.1067.3166.2365.3948.2545.5245.08
Market Capitalization431.65431.6580.61103.83105.73282.53302.77377.56679.61

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue1.691.4210.260.665.9618.6650.9238.09
Cost of Goods Sold Incl. D&A0.410.050.250.510.130.350.390.41
Gross Profit1.271.3710.010.155.8318.3150.5337.68
Selling, General and Administrative Excl. Other24.7725.1529.6828.0921.7019.6027.9120.00
Research and Development16.1017.5619.0220.7615.3113.0118.5214.41
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-23.50-23.78-19.67-27.93-15.87-1.2922.6217.68
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.00-0.100.000.000.00
Net Income Before Taxes-19.94-20.61-18.19-26.46-14.17-0.0923.5918.94
Income Taxes0.060.060.060.050.060.060.060.06
Consolidated Net Income-20.00-20.67-18.25-26.51-14.23-0.1523.5218.88
Net Income From Continuing Operations-20.00-20.67-18.25-26.51-14.23-0.1523.5218.88
Net Income-20.00-20.67-18.25-29.51-14.23-0.1523.5218.88
EPS (Recurring)-0.09-0.09-0.10-0.17-0.09-0.000.270.24
EPS (Basic, Before Extraordinaries)-0.09-0.09-0.10-0.17-0.09-0.000.270.24
EPS (Diluted)-0.09-0.09-0.10-0.17-0.09-0.000.270.24
EBITDA-23.09-23.73-19.42-27.42-15.73-0.9423.0118.09
Non-Operating Income (Expense)3.563.171.481.481.601.200.971.26
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.252.043.721.171.091.131.591.49
Price To Earnings Ratio--516.4810.195.584.581.626.07
Price To Sales Ratio42.4944.8623.449.514.632.080.380.60
Gross Margin75.4196.6997.5523.0897.7598.1499.2498.92
Operating Margin-1,392.30-1,677.08-191.77-4,212.97-266.11-6.8944.4346.41
Net Margin-1,184.72-1,457.40-177.89-4,451.28-238.62-0.8346.2049.55
Shares Outstanding217.95217.90217.69170.19165.07164.9180.6280.10
Market Capitalization431.65816.391,016.03721.79526.07357.6250.9380.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments137.05100.62174.51193.65305.23316.12296.14436.13374.11
Short Term Receivables2.513.103.4335.990.790.800.010.1010.14
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets4.363.585.007.474.297.107.189.254.35
Total Current Assets143.92107.31182.94237.10310.30324.01303.33445.48388.60
Net Property, Plant & Equipment4.7010.6016.1821.0225.3229.4532.756.934.22
Total Investments and Advances1.531.030.920.920.920.920.920.920.92
Intangible Assets1.391.531.681.821.972.122.262.412.55
Deferred Tax Assets0.932.113.363.604.615.54-1.140.40
Other Assets0.030.070.080.030.902.172.021.381.35
Total Assets152.50122.64205.15264.49344.02364.20341.28458.25398.04
Short Term Debt Incl. Current Port. of LT Debt4.245.144.594.083.623.192.810.000.00
Accounts Payable1.301.091.462.812.823.004.165.134.21
Income Tax Payable------0.0013.34-
Other Current Liabilities41.0779.54149.87145.7271.4394.7378.6279.4456.94
Total Current Liabilities46.6285.77155.91152.6177.87100.9285.5997.9161.15
Long Term Debt0.004.249.3813.9718.0621.6824.870.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.932.113.363.604.615.54-1.140.40
Other Liabilities5.9430.9883.94180.06243.94186.26179.71228.32266.60
Total Liabilities53.49123.10252.60350.24344.48314.40290.17327.36328.15
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity99.01-0.46-47.45-85.75-0.4649.8051.11130.8869.90
Total Shareholders Equity99.01-0.46-47.45-85.75-0.4649.8051.11130.8869.90
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity99.01-0.46-47.45-85.75-0.4649.8051.11130.8869.90
Total Liabilities & Stockholders Equity152.50122.64205.15264.49344.02364.20341.28458.25398.04
Book Value Per Share0.58-0.01-0.70-1.29-0.011.031.122.901.82
Tangible Book Value Per Share0.57-0.02-0.73-1.32-0.040.991.072.851.75
Full-Time Employees6912112211617414615813792
Price to Book Ratio1.51-3.44-2.023.713.176.357.405.2017.22
Return on Assets-12.6219.44-0.24-32.64-32.72-9.32-25.57-19.76-14.43
Return on Equity-35.25---5,475.03-469.64-65.17-112.35-84.28-58.09
Return on Invested Capital-17.54842.20---658.46-46.01-134.55-64.64-61.66
Quick Ratio3.091.251.171.553.983.213.544.556.36
Current Ratio3.091.251.171.553.983.213.544.556.36

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-85.42-17.3731.87-0.57-99.32-115.87-32.88-102.24-84.60
Depreciation1.221.381.772.175.865.845.462.601.88
Other Funds (Non Cash)12.508.986.554.8713.3313.4414.5518.4715.18
Funds from Operations-71.70-7.0140.186.47-80.13-96.59-12.88-81.16-67.54
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital21.49-68.58-126.42-62.51-30.65-22.4418.13-59.32-7.98
Cash from Operating Activities-50.21-75.59-86.23-56.03-110.79-119.035.26-140.48-75.52
Capital Expenditures-0.79-0.22-0.31-0.84-1.74-1.61-2.31-3.50-3.79
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.300.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-200.76-59.52100.01-149.83100.0024.10-16.4183.209.71
Purchase of Investments-420.76-192.52-155.49-424.830.00-99.90-199.11-174.99-204.60
Sale Or Maturity of Investments220.00133.00255.50275.00100.00124.00182.70258.19214.31
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-201.25-59.7499.70-150.6798.2622.49-18.7279.705.93
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock251.74110.457.5230.230.65110.2116.891.63139.62
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock251.74110.457.5230.230.65110.2116.891.63139.62
Proceedsfrom Stock Options244.67109.646.910.000.00107.7111.290.00134.60
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities251.74110.457.5230.230.65110.2116.891.63139.62
Net Change in Cash0.28-24.8920.99-176.48-11.8813.673.43-59.1570.03
Free Cash Flow-51.00-75.81-86.54-56.88-112.53-120.642.95-143.98-79.31
Preferred Dividends (Cash Flow)--0.000.000.000.000.000.000.00
Price to Free Cash Flow------102.46--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments348.90331.20346.71137.05143.63158.09
Short Term Receivables0.5037.490.652.511.631.87
Inventories0.000.000.000.000.000.00
Other Current Assets6.654.465.744.363.964.67
Total Current Assets356.05373.15353.10143.92149.22164.62
Net Property, Plant & Equipment6.196.123.354.706.547.89
Total Investments and Advances0.610.611.531.531.031.03
Intangible Assets1.281.311.351.391.421.46
Deferred Tax Assets---0.93--
Other Assets0.550.030.030.030.050.06
Total Assets364.68381.23359.36152.50158.25175.06
Short Term Debt Incl. Current Port. of LT Debt0.531.502.864.245.605.44
Accounts Payable1.141.941.371.300.650.23
Other Current Liabilities43.8736.4329.8041.0734.7933.55
Total Current Liabilities45.5339.8634.0246.6241.0339.22
Long Term Debt3.864.210.000.000.001.44
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---0.93--
Other Liabilities30.4035.095.395.949.8414.48
Total Liabilities79.7979.1639.4153.4950.8755.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity284.89302.07319.9499.01107.39119.91
Total Shareholders Equity284.89302.07319.9499.01107.39119.91
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity284.89302.07319.9499.01107.39119.91
Total Liabilities & Stockholders Equity364.68381.23359.36152.50158.25175.06
Book Value Per Share1.311.391.470.580.650.73
Tangible Book Value Per Share1.301.381.460.570.640.72
Full-Time Employees---69--
Price to Book Ratio1.512.558.086.554.397.31
Return on Assets-32.67-28.64-25.83-12.6218.8528.71
Return on Equity-43.55-37.75-34.29-35.2566.76108.21
Return on Invested Capital-6.93-6.75-5.70-26.78-13.25-0.13
Quick Ratio7.829.3610.383.093.644.20
Current Ratio7.829.3610.383.093.644.20

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-20.00-20.67-18.25-26.51-14.23-0.15
Depreciation0.410.050.250.510.130.35
Other Funds (Non Cash)2.552.515.112.321.882.14
Funds from Operations-17.04-18.11-12.88-23.68-12.212.33
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital33.680.04-12.660.43-3.33-18.09
Cash from Operating Activities16.65-18.07-25.55-23.24-15.55-15.75
Capital Expenditures-0.590.000.00-0.200.13-0.03
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.300.000.000.000.000.00
Purchase or Sale of Investments0.295.95-192.78-14.220.31-76.33
Purchase of Investments-64.71-69.05-242.78-44.22-19.69-108.83
Sale Or Maturity of Investments65.0075.0050.0030.0020.0032.50
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.005.95-192.78-14.420.44-76.36
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00-0.000.00
Change in Capital Stock0.090.51234.4916.640.2593.55
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.090.51234.4916.640.2593.55
Proceedsfrom Stock Options0.000.06228.3516.260.0093.37
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.090.51234.4916.640.2593.55
Net Change in Cash16.74-11.6016.16-21.02-14.861.44
Free Cash Flow16.06-18.07-25.55-23.44-15.42-15.78

Revenue breakdown

Pharmaceutical Preparations2024: 138.10M 2025: 76.20M
United States2024: 138.10M 2025: 76.20M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3025.60%45.2M176.8M3.50M
2026-10-1524.22%42.8M176.7M3.36M
2026-09-3023.12%40.8M176.5M3.49M
2026-09-1521.29%38.6M181.5M4.03M
2026-08-3117.61%33.5M190.3M3.93M
2026-08-1419.08%34.6M181.5M4.00M
2026-07-3120.26%35.1M173.3M4.12M
2026-07-1523.29%40.3M173.1M4.23M
2026-06-3019.34%35.6M183.9M4.42M
2026-06-1517.68%30.6M173.1M6.80M
2026-05-2916.59%28.7M173.1M6.75M
2026-05-1518.64%31.1M167.1M6.66M
2026-04-3017.43%29.7M170.6M6.82M
2026-04-1516.24%27.5M169.4M7.03M
2026-03-3113.04%22.0M169.0M6.55M
2026-03-1315.34%20.4M133.1M3.26M
2026-02-2714.24%18.9M132.5M3.02M
2026-02-1312.80%17.0M132.5M3.03M
2026-01-3011.63%14.8M127.4M3.28M
2026-01-1512.61%16.1M127.9M2.93M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.152.050.0022.2230.000.000.968-0.0100.000
call1.000.501.501.409.53059.000.000.935-0.0100.000
call1.500.151.050.856.4092.000.000.882-0.0080.001
call2.000.100.200.300.9562940.000.670-0.0080.001
call3.000.000.050.052.1501780.000.159-0.0090.001
call4.000.000.050.052.9286190.000.125-0.0110.001
call5.000.000.050.043.7214080.000.109-0.0120.001
call6.000.000.500.054.1393650.000.099-0.0130.001
call7.000.000.750.154.52717.000.000.092-0.0140.001
call8.000.000.350.104.8771100.000.088-0.0150.001
call9.000.000.950.005.2060.000.000.085-0.0150.001
call10.000.000.950.055.4515.000.000.082-0.0150.001
call11.000.000.750.005.6840.000.000.080-0.0160.000
call12.000.000.750.115.8941.000.000.078-0.0160.000
call13.000.000.750.056.0994.000.000.077-0.0160.000
put0.500.000.050.006.7240.000.00-0.036-0.0090.000
put1.000.000.050.006.5710.000.00-0.114-0.0220.001
put1.500.000.050.103.8210.000.00-0.208-0.0190.001
put2.000.000.100.011.9714,5020.00-0.369-0.0120.001
put3.000.451.001.052.8383.000.00-0.834-0.0090.001
put4.001.552.502.057.8744,2350.00-0.875-0.0110.001
put5.002.503.502.378.7560.000.00-0.892-0.0120.001
put6.003.504.500.009.4010.000.00-0.902-0.0130.001
put7.004.505.500.009.9200.000.00-0.908-0.0130.001
put8.005.506.500.0010.3530.000.00-0.912-0.0140.001
put9.006.507.500.0010.7240.000.00-0.916-0.0140.001
put10.007.508.500.0011.0470.000.00-0.918-0.0140.001
put11.007.4010.500.0020.3820.000.00-0.920-0.0140.000
put12.009.2010.700.0013.0250.000.00-0.922-0.0150.000
put13.0010.0012.400.0019.5770.000.00-0.923-0.0150.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-28SCHEDULE 13G/ASEC
2026-10-164/A2025-11-06SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-053Initial statement of beneficial ownership of securities2026-08-03SEC
2026-08-03SCHEDULE 13GSEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-24SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-24SEC
2026-07-27SCHEDULE 13GSEC
2026-07-278-KCurrent report2026-07-24SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-228-KCurrent report2026-06-17SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-06-038-KCurrent report2026-05-29SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-06004.95K1
2026-050000
2026-040000
2026-03001.23M4
2026-020000
2026-010000
2025-120000
2025-1100461.91K1

Institutional holders

Manager% owned
FMR LLC15.76%
Kynam Capital Management, LP9.97%
BlackRock, Inc.8.07%
BANK OF AMERICA CORP /DE/6.93%
STATE STREET CORP5.40%
PERCEPTIVE ADVISORS LLC4.80%
VANGUARD CAPITAL MANAGEMENT LLC3.92%
Point72 Asset Management, L.P.3.59%
WELLINGTON MANAGEMENT GROUP LLP2.37%
GEODE CAPITAL MANAGEMENT, LLC2.34%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.66%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
Select Health Care Portfolio2.75%
iShares Russell 2000 ETF2.12%
Fidelity Small Cap Growth Fund1.82%
Strategic Advisers Fidelity U.S. Total Stock Fund1.72%
Select Biotechnology Portfolio1.28%
Fidelity Advisor Health Care Fund1.15%
Fidelity Advisor Biotechnology Fund1.14%
Fidelity Stock Selector Small Cap Fund1.13%

OakChart. CTMX. Cached 15 minutes.